This website uses cookies. For more information please contact us or consult our privacy policy.
Your binder contains too many pages, the maximum is 40.
We are unable to add this page to your binder, please try again later.
This page has been added to your binder.
Lundbeck Loses Appeal Against ‘Pay-For-Delay’ Decision
September 12, 2016 , Covington Alert
The General Court (the “GC” or the “Court”) delivered its judgment in the Lundbeck ‘pay-for-delay’ case last Thursday (Case T-472/13 Lundbeck v Commission). In its judgment, the GC confirms the European Commission (the “Commission”)’s decision (the “Decision”), namely that the agreements between Lundbeck and the generic producers (Merck KGaA/Generics UK (“GUK”), Alpharma, Arrow and Ranbaxy) restricted competition ‘by object’ in violation of Art. 101(1) of the Treaty on the Functioning of the European Union (“TFEU”).
June 16, 2017
LONDON—Euromoney Legal Media Group has selected three Covington lawyers for its annual “Europe Women in Business Law Awards.” The awards honor women in the legal sector across Europe. The Covington lawyers recognized are: Louise Nash, Best in Mergers & Acquisitions. Ms. Nash focuses on M&A and other transactional matters for clients in the consumer brands, ...
Two Covington Partners on GCR’s Women in Antitrust List
December 2, 2016
LONDON—Global Competition Review has named two Covington partners to its Women in Antitrust list. Now in its fifth year, the report aims to identify and celebrate achievements of elite female antitrust professionals in private practice, as well as expert economists, in-house counsel, enforcers, and academics around the world. Miranda Cole is a partner based in ...
October 21, 2016
WASHINGTON—Covington represented India-based Piramal Enterprises and its wholly owned Critical Care subsidiary in the UK in the acquisition of five anesthesia and pain management injectable products from Janssen Pharmaceutica NV, in an all cash deal for an upfront consideration of US$155 million, and up to an additional US$20 million. The products to be acquired ...